Laboratory Characteristics in Chronic Atrophic Acrodermatitis
NCT ID: NCT02147262
Last Updated: 2018-05-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2013-07-31
2020-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Doxycycline in Therapy of Erythema Migrans
NCT01475708
Inflammatory Mediators in Erythema Migrans
NCT03956212
Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome
NCT01518192
Duration of Doxycycline Treatment in EM Patients
NCT03153267
Cytokines and Chemokines in Erythema Migrans
NCT02147249
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ACA-doxy 14 days
patients with chronic atrophic acrodermatitis treated with doxycycline for 14 days
doxycycline orally, 100 mg, bid, 14 days
ACA-doxy 28 days
patients with chronic atrophic acrodermatitis treated with doxycycline for 28 days
doxycycline orally, 100 mg, bid, 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
doxycycline orally, 100 mg, bid, 14 days
doxycycline orally, 100 mg, bid, 28 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Ljubljana School of Medicine, Slovenia
OTHER
Medical University of Vienna
OTHER
Harvard University
OTHER
University Medical Centre Ljubljana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Franc Strle
M.D., PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Franc Strle, MD, PhD
Role: STUDY_CHAIR
UMC Ljubljana
Dasa Stupica, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
UMC Ljubljana
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UMC Ljubljana, Department of Infectious Diseases
Ljubljana, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACA-0613
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.